indazoles has been researched along with fosbretabulin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cai, X; Duan, JX; Hart, C; Lan, L; Matteucci, M; Meng, F | 1 |
| Banerjee, S; Clamp, AR; Dive, C; Hall, M; Hasan, J; Jayson, GC; Lyon, AR; Morgan, RD; Orbegoso, C; Rustin, GJS; Taylor, S; Tugwood, J; Zhou, C | 1 |
1 trial(s) available for indazoles and fosbretabulin
| Article | Year |
|---|---|
Pazopanib and Fosbretabulin in recurrent ovarian cancer (PAZOFOS): A multi-centre, phase 1b and open-label, randomised phase 2 trial.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cardiotoxicity; Dose-Response Relationship, Drug; Female; Humans; Indazoles; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Ovarian Neoplasms; Progression-Free Survival; Pyrimidines; Stilbenes; Sulfonamides; Survival Rate | 2020 |
1 other study(ies) available for indazoles and fosbretabulin
| Article | Year |
|---|---|
Potent antitubulin tumor cell cytotoxins based on 3-aroyl indazoles.
Topics: Acetylene; Animals; Binding Sites; Binding, Competitive; Cattle; Cell Line, Tumor; Colchicine; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Humans; Indazoles; Radioligand Assay; Stilbenes; Structure-Activity Relationship; Tubulin; Tubulin Modulators | 2007 |